Moses Makunje
Directeur Financier/CFO chez NUVATION BIO INC.
Fortune : 27 803 $ au 30/04/2024
Postes actifs de Moses Makunje
Sociétés | Poste | Début | Fin |
---|---|---|---|
NUVATION BIO INC. | Comptroller/Controller/Auditor | 27/11/2023 | - |
Directeur Financier/CFO | 27/11/2023 | - | |
Corporate Officer/Principal | 01/07/2020 | 27/11/2023 |
Historique de carrière de Moses Makunje
Anciens postes connus de Moses Makunje
Sociétés | Poste | Début | Fin |
---|---|---|---|
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Comptroller/Controller/Auditor | 01/03/2019 | 01/07/2020 |
Statistiques
Internationale
Etats-Unis | 3 |
Opérationnelle
Comptroller/Controller/Auditor | 2 |
Director of Finance/CFO | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
NUVATION BIO INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Commercial Services |
- Bourse
- Insiders
- Moses Makunje
- Expérience